Human CDR-grafted antibody and antibody fragment thereof
View Patent ↗A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
1. A method for treating cancer in a patient, said method comprising administering to a patient in need thereof an effective amount of a human CDR-grafted antibody or antibody fragment thereof which reacts with an extracellular region of human CC chemokine receptor 4 (CCR4), wherein the antibody or antibody fragment thereof comprises complementarity determining regions (CDRs) 1-3 of a heavy chain variable region which comprise the amino acid sequences of SEQ ID NOs: 1-3, respectively, and CDRs 1-3 of a light chain variable region which comprise the amino acid sequences of SEQ ID NOs: 5-7, respectively,
and wherein cancer cells of the cancer express CCR4.
2. The method according to claim 1 , wherein the cancer is a blood cancer.
3. The method according to claim 2 , wherein the cancer is a leukemia or a lymphoma.
4. The method according to claim 1 , wherein the human CDR-grafted antibody or antibody fragment thereof comprises an antibody heavy chain (H chain) variable region (V region) comprising SEQ ID NO: 4, 9, 10, 11, 38, 39, 40 or 41, and a light chain (L chain) V region comprising SEQ ID NO: 8, 12, 13 or 14.
5. The method according to claim 1 , wherein the human CDR-grafted antibody or antibody fragment thereof is an antibody obtainable from a transformant KM8759 (FERM BP-8129) or KM8760 (FERM BP-8130).